StockNews.AI
MRVI
StockNews.AI
90 days

Maravai LifeSciences Releases 2024 Sustainability Report

1. Maravai launched 49 new products, enhancing its innovation capacity. 2. A new GMP facility increases mRNA production by tenfold. 3. R. Andrew Eckert appointed as independent Chairman of the Board. 4. Sustainability efforts include expanded greenhouse gas emissions reporting. 5. Employee engagement remains high with a 95% participation rate.

6m saved
Insight
Article

FAQ

Why Bullish?

The significant product innovation and new facility likely enhance competitive advantage, driving sales.

How important is it?

Enhanced innovation and governance structure strengthen Maravai's market position and long-term potential.

Why Long Term?

Ongoing product development and sustainability initiatives are likely to yield sustained growth.

Related Companies

BMYMRNAPFE
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company’s Sustainability webpage (investors.maravai.com/sustainability). The new report highlights progress during calendar year 2024 across Maravai’s four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company’s commitment to sustainable value creation. “By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,” said Trey Martin, Chief Executive Officer. “Our 2024 achievements position Maravai to remain our customers’ first choice as they advance their programs in next-generation therapeutics and diagnostics.” Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP qualityCompleted state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfoldEstablished RNA Innovation Center in collaboration with Johns Hopkins UniversityAdded to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 commentsExpanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organizationImplemented new career framework creating transparent progression paths for all employeesContinued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the BoardAdopted formal, publicly available Human Rights Policy100% of standing Board Committees chaired by independent membersStrengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reportingLeland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy useSan Diego EV charging stations helped save over 19,000 gallons of gasolineAdvanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai’s most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law.

Related News